Home>Topics>>Buy MAP Pharmaceutical For 70% Upside
Buy MAP Pharmaceutical For 70% Upside
Healthcare Sector and Stocks Analysis from Seeking Alpha
Mon, 26 Nov 2012
By Stock Whisper : MAP Pharmaceuticals ( MAPP ) saw an appreciation of 20% on Friday. We believe this is just the start of an epic run for MAPP shareholders. The company's application for LEVADEX was rejected by FDA back in March due to CMC issues and no objections were made on efficacy or safety. ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.